| Mk-AG | Mk-AT | Mk-AF | Mk-AC | Mk-AM | Mk-CS | Mk-CB | Mk-CC | Mk-CH | Mk-IR | Mk-IE | Mk-IZ | Mk-IRh | Mk-IG |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
species | fasc. | fasc. | mul. | fasc. | fasc. | mul. | fasc. | fasc. | fasc. | mul. | mul. | fasc. | mul. | mul |
Antibody Treatment | Anti-Nogo-A (hNogo) | Anti-Nogo-A (hNogo) | Anti-Nogo-A (11C7) | Anti- Nogo-A (hNogo) | Anti-Nogo-A (hNogo) | Contr. | Contr. | Contr. | Contr. | - | - | - | - | - |
Hemi-section total extent (%) | 78 | * | 56 | 85 | 80 | 63 | 75 | 38 | 90 | - | - | - | - | - |
Completeness of dorsolateral funiculus section | Yes | * | Yes | Yes | Yes | Yes | Yes | No | Yes | - | - | - | - | - |
RS and CS lesion extent (%) | 100 | * | 73 | 100 | 100 | 87 | 93 | 61 | 100 | - | - | - | - | - |
Functional Recovery (%) | 100 | (100)* | 57 | 100 | 96 | 22 | 78 | 83 | 53 | - | - | - | - | - |
Completeness of CS/RS section | Yes | * | No | Yes | Yes | Yes | Yes | No | Yes | - | - | - | - | - |
Survival time after lesion (in days) | 112 | 97 | 144 | 135 | 138 | 198 | 225 | 105 | 138 | - | - | - | - | - |
ICMS | no | no | yes | no | no | yes | no | yes | no | no | no | no | no | no |